Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL DERMATITIS MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL DERMATITIS MARKET SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 EPIDEMIOLOGY MODELING
2.2.12 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.13 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL DERMATITIS MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PORTER'S 5 FORCES
4.2 PESTEL ANALYSIS
5 EPIDEMIOLOGY
5.1 PREVALECE OF ATOPIC DERMATITIS, BY COUNTRY
5.2 PREVALECE OF CONTACT DERMATITIS, BY COUNTRY
5.3 PREVALECE OF DYSHIDROTIC DERMATITIS, BY COUNTRY
5.4 PREVALECE OF SEBORRHEIC DERMATITIS, BY COUNTRY
5.5 PREVALECE OF ATOPIC DERMATITIS, BY COUNTRY
5.6 PREVALECE OF STASIS DERMATITIS, BY COUNTRY
5.7 TREATMENT RATE
5.8 MORTALITY RATE
5.9 DRUG ADHERENCE AND THERAPY SWITCH MODEL
5.1 PATEINT TREATMENT SUCCESS RATES
6 INDUSTRY INSIGHTS
6.1 PATENT ANALYSIS
6.2 DRUG TREATMENT RATE BY MATURED MARKETS
6.3 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES
6.4 PATIENT FLOW DIAGRAM
6.5 KEY PRICING STRATEGIES
6.6 KEY PATIENT ENROLLMENT STRATEGIES
6.7 INTERVIEWS WITH DERMATOLOGIST
6.8 OTHER KOL SNAPSHOTS
7 REGULATORY SCENARIO
7.1 FDA APPROVALS
7.2 EMA APPROVALS
8 MERGERS AND ACQUISITION
8.1 LICENSING
8.2 COMMERCIALIZATION AGREEMENTS
9 PIPELINE ANALYSIS
9.1 CLINICAL TRIALS AND PHASE ANALYSIS
9.2 DRUG THERAPY PIPELINE
9.3 PHASE III CANDIDATES
9.3.1 BARICITNIB
9.3.2 UPADACITNIB
9.3.3 RUXOLITIIB
9.3.4 ABROCITNIB
9.3.5 NEMOLIZUMAB
9.3.6 LEBRIKIZUMAB
9.3.7 KHK-4083
9.3.8 OTHERS
9.4 PHASE II CANDIDATES
9.4.1 TOFACITNIB
9.4.2 GUSACITNIB
9.4.3 RISANKIZUMAB
9.4.4 BERMEKIMAB
9.4.5 OTHERS
9.5 PHASE I CANDIDATES
9.6 OTHERS (PRE-CLINICAL AND RESEARCH)
10 MARKET OVERVIEW
10.1 DRIVERS
10.2 RESTRAINS
10.3 OPPURTUNITY
10.4 CHALLENGES
11 GLOBAL DERMATITIS MARKET, BY TREATMENT
11.1 OVERVIEW
11.2 PHOSPHODIESTERASE-4 INHIBITORS
11.2.1 BY DRUGS
11.2.1.1. APREMILAST
11.2.1.1.1. MARKET VALUE (USD MN)
11.2.1.1.2. MARKET VOLUME (IU)
11.2.1.1.3. AVERAGE SELLING PRICE (USD)
11.2.1.2. CRISABOROLE
11.2.1.2.1. MARKET VALUE (USD MN)
11.2.1.2.2. MARKET VOLUME (IU)
11.2.1.2.3. AVERAGE SELLING PRICE (USD)
11.2.1.3. ROFLUMILAST
11.2.1.3.1. MARKET VALUE (USD MN)
11.2.1.3.2. MARKET VOLUME (IU)
11.2.1.3.3. AVERAGE SELLING PRICE (USD)
11.2.1.4. OTHERS
11.2.2 BY DRUG TYPE
11.2.2.1. GENERICS
11.2.2.2. BRANDED
11.2.2.2.1. OTEZLA
11.2.2.2.1.1 MARKET VALUE (USD MN)
11.2.2.2.1.2 MARKET VOLUME (IU)
11.2.2.2.1.3 AVERAGE SELLING PRICE (USD)
11.2.2.2.2. EUCRIS
11.2.2.2.2.1 MARKET VALUE (USD MN)
11.2.2.2.2.2 MARKET VOLUME (IU)
11.2.2.2.2.3 AVERAGE SELLING PRICE (USD)
11.2.2.2.3. DAXAS
11.2.2.2.3.1 MARKET VALUE (USD MN)
11.2.2.2.3.2 MARKET VOLUME (IU)
11.2.2.2.3.3 AVERAGE SELLING PRICE (USD)
11.2.2.2.4. OTHERS
11.3 CALCINEURIN INHIBITORS
11.3.1 BY DRUGS
11.3.1.1. TACROLIMUS
11.3.1.1.1. MARKET VALUE (USD MN)
11.3.1.1.2. MARKET VOLUME (IU)
11.3.1.1.3. AVERAGE SELLING PRICE (USD)
11.3.1.2. PIMCROMILUS
11.3.1.2.1. MARKET VALUE (USD MN)
11.3.1.2.2. MARKET VOLUME (IU)
11.3.1.2.3. AVERAGE SELLING PRICE (USD)
11.3.1.3. OTHERS
11.3.2 BY DRUG TYPE
11.3.2.1. GENERICS
11.3.2.2. BRANDED
11.3.2.2.1. PROTOPIC
11.3.2.2.1.1 MARKET VALUE (USD MN)
11.3.2.2.1.2 MARKET VOLUME (IU)
11.3.2.2.1.3 AVERAGE SELLING PRICE (USD)
11.3.2.2.2. ELIDEL
11.3.2.2.2.1 MARKET VALUE (USD MN)
11.3.2.2.2.2 MARKET VOLUME (IU)
11.3.2.2.2.3 AVERAGE SELLING PRICE (USD)
11.3.2.2.3. OTHERS
11.4 BIOLOGICS
11.4.1 DUPLIMAB
11.4.1.1. MARKET VALUE (USD MN)
11.4.1.2. MARKET VOLUME (IU)
11.4.1.3. AVERAGE SELLING PRICE (USD)
11.4.2 TRALOKINUMAB
11.4.2.1. MARKET VALUE (USD MN)
11.4.2.2. MARKET VOLUME (IU)
11.4.2.3. AVERAGE SELLING PRICE (USD)
11.4.3 OTHERS
11.5 SOOTHING PRODUCTS
11.5.1 CALAMINE LOTION
11.5.1.1. MARKET VALUE (USD MN)
11.5.1.2. MARKET VOLUME (IU)
11.5.1.3. AVERAGE SELLING PRICE (USD)
11.5.2 COLLOIDAL OATMEAL
11.5.2.1. MARKET VALUE (USD MN)
11.5.2.2. MARKET VOLUME (IU)
11.5.2.3. AVERAGE SELLING PRICE (USD)
11.5.3 OTHERS
11.6 CORTICOSTEROIDS
11.6.1 BY DRUGS
11.6.1.1. BETAMETHASONE
11.6.1.1.1. MARKET VALUE (USD MN)
11.6.1.1.2. MARKET VOLUME (IU)
11.6.1.1.3. AVERAGE SELLING PRICE (USD)
11.6.1.2. CLOBETASOL
11.6.1.2.1. MARKET VALUE (USD MN)
11.6.1.2.2. MARKET VOLUME (IU)
11.6.1.2.3. AVERAGE SELLING PRICE (USD)
11.6.1.3. FLUOCINONIDE
11.6.1.3.1. MARKET VALUE (USD MN)
11.6.1.3.2. MARKET VOLUME (IU)
11.6.1.3.3. AVERAGE SELLING PRICE (USD)
11.6.1.4. HALOBETASOL
11.6.1.4.1. MARKET VALUE (USD MN)
11.6.1.4.2. MARKET VOLUME (IU)
11.6.1.4.3. AVERAGE SELLING PRICE (USD)
11.6.1.5. FLURANDRENOLIDE
11.6.1.5.1. MARKET VALUE (USD MN)
11.6.1.5.2. MARKET VOLUME (IU)
11.6.1.5.3. AVERAGE SELLING PRICE (USD)
11.6.1.6. AMCINONIDE
11.6.1.6.1. MARKET VALUE (USD MN)
11.6.1.6.2. MARKET VOLUME (IU)
11.6.1.6.3. AVERAGE SELLING PRICE (USD)
11.6.1.7. HYDROCORTISONE
11.6.1.7.1. MARKET VALUE (USD MN)
11.6.1.7.2. MARKET VOLUME (IU)
11.6.1.7.3. AVERAGE SELLING PRICE (USD)
11.6.1.8. TRIAMCINOLONE
11.6.1.8.1. MARKET VALUE (USD MN)
11.6.1.8.2. MARKET VOLUME (IU)
11.6.1.8.3. AVERAGE SELLING PRICE (USD)
11.6.1.9. OTHERS
11.6.2 BY DRUG TYPE
11.6.2.1. GENERICS
11.6.2.2. BRANDED
11.6.2.2.1. CELESTONE
11.6.2.2.1.1 MARKET VALUE (USD MN)
11.6.2.2.1.2 MARKET VOLUME (IU)
11.6.2.2.1.3 AVERAGE SELLING PRICE (USD)
11.6.2.2.2. TEMOVATE
11.6.2.2.2.1 MARKET VALUE (USD MN)
11.6.2.2.2.2 MARKET VOLUME (IU)
11.6.2.2.2.3 AVERAGE SELLING PRICE (USD)
11.6.2.2.3. VANOS
11.6.2.2.3.1 MARKET VALUE (USD MN)
11.6.2.2.3.2 MARKET VOLUME (IU)
11.6.2.2.3.3 AVERAGE SELLING PRICE (USD)
11.6.2.2.4. CYCLOCORT
11.6.2.2.4.1 MARKET VALUE (USD MN)
11.6.2.2.4.2 MARKET VOLUME (IU)
11.6.2.2.4.3 AVERAGE SELLING PRICE (USD)
11.6.2.2.5. ULTRAVATE
11.6.2.2.5.1 MARKET VALUE (USD MN)
11.6.2.2.5.2 MARKET VOLUME (IU)
11.6.2.2.5.3 AVERAGE SELLING PRICE (USD)
11.6.2.2.6. HYDROCORT
11.6.2.2.6.1 MARKET VALUE (USD MN)
11.6.2.2.6.2 MARKET VOLUME (IU)
11.6.2.2.6.3 AVERAGE SELLING PRICE (USD)
11.6.2.2.7. ALPHOSYL
11.6.2.2.7.1 MARKET VALUE (USD MN)
11.6.2.2.7.2 MARKET VOLUME (IU)
11.6.2.2.7.3 AVERAGE SELLING PRICE (USD)
11.6.2.2.8. KENALOG
11.6.2.2.8.1 MARKET VALUE (USD MN)
11.6.2.2.8.2 MARKET VOLUME (IU)
11.6.2.2.8.3 AVERAGE SELLING PRICE (USD)
11.6.2.2.9. ARISTOSPAN
11.6.2.2.9.1 MARKET VALUE (USD MN)
11.6.2.2.9.2 MARKET VOLUME (IU)
11.6.2.2.9.3 AVERAGE SELLING PRICE (USD)
11.6.2.2.10. OTHERS
11.7 ANTIHISTAMINES
11.7.1 BY DRUGS
11.7.1.1. DIPHENHYDRAMINE
11.7.1.1.1. MARKET VALUE (USD MN)
11.7.1.1.2. MARKET VOLUME (IU)
11.7.1.1.3. AVERAGE SELLING PRICE (USD)
11.7.1.2. CHLORPHENIRAMINE
11.7.1.2.1. MARKET VALUE (USD MN)
11.7.1.2.2. MARKET VOLUME (IU)
11.7.1.2.3. AVERAGE SELLING PRICE (USD)
11.7.1.3. CLEMASTINE
11.7.1.3.1. MARKET VALUE (USD MN)
11.7.1.3.2. MARKET VOLUME (IU)
11.7.1.3.3. AVERAGE SELLING PRICE (USD)
11.7.1.4. FEXOFENADINE
11.7.1.4.1. MARKET VALUE (USD MN)
11.7.1.4.2. MARKET VOLUME (IU)
11.7.1.4.3. AVERAGE SELLING PRICE (USD)
11.7.1.5. LORATADINE
11.7.1.5.1. MARKET VALUE (USD MN)
11.7.1.5.2. MARKET VOLUME (IU)
11.7.1.5.3. VERAGE SELLING PRICE (USD)
11.7.1.6. CETRIZINE
11.7.1.6.1. MARKET VALUE (USD MN)
11.7.1.6.2. MARKET VOLUME (IU)
11.7.1.6.3. AVERAGE SELLING PRICE (USD)
11.7.1.7. CLEMASTINE
11.7.1.7.1. MARKET VALUE (USD MN)
11.7.1.7.2. MARKET VOLUME (IU)
11.7.1.7.3. AVERAGE SELLING PRICE (USD)
11.7.1.8. OTHERS
11.7.2 BY DRUG TYPE
11.7.2.1. GENERICS
11.7.2.2. BRANDED
11.7.2.2.1. DYTAN DM
11.7.2.2.1.1 MARKET VALUE (USD MN)
11.7.2.2.1.2 MARKET VOLUME (IU)
11.7.2.2.1.3 AVERAGE SELLING PRICE (USD)
11.7.2.2.2. CHLOR TRIMETON
11.7.2.2.2.1 MARKET VALUE (USD MN)
11.7.2.2.2.2 MARKET VOLUME (IU)
11.7.2.2.2.3 AVERAGE SELLING PRICE (USD)
11.7.2.2.3. TAVIST ALLERGY
11.7.2.2.3.1 MARKET VALUE (USD MN)
11.7.2.2.3.2 MARKET VOLUME (IU)
11.7.2.2.3.3 AVERAGE SELLING PRICE (USD)
11.7.2.2.4. ALLEGRA
11.7.2.2.4.1 MARKET VALUE (USD MN)
11.7.2.2.4.2 MARKET VOLUME (IU)
11.7.2.2.4.3 AVERAGE SELLING PRICE (USD)
11.7.2.2.5. CLARITIN
11.7.2.2.5.1 MARKET VALUE (USD MN)
11.7.2.2.5.2 MARKET VOLUME (IU)
11.7.2.2.5.3 AVERAGE SELLING PRICE (USD)
11.7.2.2.6. ZYRTEC
11.7.2.2.6.1 MARKET VALUE (USD MN)
11.7.2.2.6.2 MARKET VOLUME (IU)
11.7.2.2.6.3 AVERAGE SELLING PRICE (USD)
11.7.2.2.7. OTHERS
11.8 ANTIBIOTICS
11.8.1 BY DRUGS
11.8.1.1. ERYTHROMYCIN
11.8.1.1.1. MARKET VALUE (USD MN)
11.8.1.1.2. MARKET VOLUME (IU)
11.8.1.1.3. AVERAGE SELLING PRICE (USD)
11.8.1.2. SULFACETAMIDE
11.8.1.2.1. MARKET VALUE (USD MN)
11.8.1.2.2. MARKET VOLUME (IU)
11.8.1.2.3. AVERAGE SELLING PRICE (USD)
11.8.1.3. NEOMYCIN
11.8.1.3.1. MARKET VALUE (USD MN)
11.8.1.3.2. MARKET VOLUME (IU)
11.8.1.3.3. AVERAGE SELLING PRICE (USD)
11.8.1.4. VANCOMYCIN
11.8.1.4.1. MARKET VALUE (USD MN)
11.8.1.4.2. MARKET VOLUME (IU)
11.8.1.4.3. AVERAGE SELLING PRICE (USD)
11.8.1.5. LINEZOLID
11.8.1.5.1. MARKET VALUE (USD MN)
11.8.1.5.2. MARKET VOLUME (IU)
11.8.1.5.3. AVERAGE SELLING PRICE (USD)
11.8.1.6. CEFTAROLINE
11.8.1.6.1. MARKET VALUE (USD MN)
11.8.1.6.2. MARKET VOLUME (IU)
11.8.1.6.3. AVERAGE SELLING PRICE (USD)
11.8.1.7. DAPTOMYCIN
11.8.1.7.1. MARKET VALUE (USD MN)
11.8.1.7.2. MARKET VOLUME (IU)
11.8.1.7.3. AVERAGE SELLING PRICE (USD)
11.8.1.8. OFLOXACIN
11.8.1.8.1. MARKET VALUE (USD MN)
11.8.1.8.2. MARKET VOLUME (IU)
11.8.1.8.3. AVERAGE SELLING PRICE (USD)
11.8.1.9. CIPROFLOXACIN
11.8.1.9.1. MARKET VALUE (USD MN)
11.8.1.9.2. MARKET VOLUME (IU)
11.8.1.9.3. AVERAGE SELLING PRICE (USD)
11.8.1.10. OTHERS
11.8.2 BY DRUG TYPE
11.8.2.1. GENERICS
11.8.2.2. BRANDED
11.8.2.2.1. KLARON
11.8.2.2.1.1 MARKET VALUE (USD MN)
11.8.2.2.1.2 MARKET VOLUME (IU)
11.8.2.2.1.3 AVERAGE SELLING PRICE (USD)
11.8.2.2.2. OVACE
11.8.2.2.2.1 MARKET VALUE (USD MN)
11.8.2.2.2.2 MARKET VOLUME (IU)
11.8.2.2.2.3 AVERAGE SELLING PRICE (USD)
11.8.2.2.3. VANCOCIN
11.8.2.2.3.1 MARKET VALUE (USD MN)
11.8.2.2.3.2 MARKET VOLUME (IU)
11.8.2.2.3.3 AVERAGE SELLING PRICE (USD)
11.8.2.2.4. ZYVOX
11.8.2.2.4.1 MARKET VALUE (USD MN)
11.8.2.2.4.2 MARKET VOLUME (IU)
11.8.2.2.4.3 AVERAGE SELLING PRICE (USD)
11.8.2.2.5. TEFLARO
11.8.2.2.5.1 MARKET VALUE (USD MN)
11.8.2.2.5.2 MARKET VOLUME (IU)
11.8.2.2.5.3 AVERAGE SELLING PRICE (USD)
11.8.2.2.6. CUBICIN
11.8.2.2.6.1 MARKET VALUE (USD MN)
11.8.2.2.6.2 MARKET VOLUME (IU)
11.8.2.2.6.3 AVERAGE SELLING PRICE (USD)
11.8.2.2.7. FLOXIN
11.8.2.2.7.1 MARKET VALUE (USD MN)
11.8.2.2.7.2 MARKET VOLUME (IU)
11.8.2.2.7.3 AVERAGE SELLING PRICE (USD)
11.8.2.2.8. CIPRO
11.8.2.2.8.1 MARKET VALUE (USD MN)
11.8.2.2.8.2 MARKET VOLUME (IU)
11.8.2.2.8.3 AVERAGE SELLING PRICE (USD)
11.8.2.2.9. OTHERS
12 GLOBAL DERMATITIS MARKET, BY ROUTE OF ADMINISTRATION
12.1 OVERVIEW
12.2 TOPICAL
12.2.1 CREAM
12.2.2 LOTION
12.2.3 OINTMENT
12.2.4 SPRAY
12.2.5 OTHERS
12.3 ORAL
12.3.1 TABLET
12.3.2 CALPSULES
12.3.3 SYRUP
12.3.4 OTHERS
12.4 OTHERS
12.5 RECONSTITUTE
13 GLOBAL DERMATITIS MARKET, BY END USER
13.1 OVERVIEW
13.2 HOSPITALS
13.3 DERMATOLOGY CLINICS
13.4 ACADEMIC AND RESEARCH INSTITUTES
13.5 OTHERS
14 GLOBAL DERMATITIS MARKET, BY DISTRIBUTION CHANNEL
14.1 OVERVIEW
14.2 HOSPITAL PHARMACY
14.3 ONLINE PHARMACY
14.4 RETAIL PHARMACY
15 GLOBAL DERMATITIS MARKET, BY GEOGRAPHY
15.1 GLOBAL DERMATITIS MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
15.2 NORTH AMERICA
15.2.1 U.S.
15.2.1.1. U.S. DERMATITIS MARKET, BY TREATMENT TYPE
15.2.1.2. U.S. DERMATITIS MARKET, BY ROUTE OF ADMINISTRATION
15.2.1.3. U.S. DERMATITIS MARKET, BY END USER
15.2.1.4. U.S. DERMATITIS MARKET, BY DISTRIBUTION CHANNEL
15.2.2 CANADA
15.2.3 MEXICO
15.2.4 DOMINICAN REPUBLIC
15.2.5 JAMAICA
15.2.6 PANAMA
15.3 EUROPE
15.3.1 GERMANY
15.3.2 FRANCE
15.3.3 U.K.
15.3.4 HUNGARY
15.3.5 LITHUANIA
15.3.6 AUSTRIA
15.3.7 IRELAND
15.3.8 NORWAY
15.3.9 POLAND
15.3.10 ITALY
15.3.11 SPAIN
15.3.12 RUSSIA
15.3.13 TURKEY
15.3.14 NETHERLANDS
15.3.15 SWITZERLAND
15.3.16 REST OF EUROPE
15.4 ASIA-PACIFIC
15.4.1 JAPAN
15.4.2 CHINA
15.4.3 TAIWAN
15.4.4 SOUTH KOREA
15.4.5 INDIA
15.4.6 AUSTRALIA
15.4.7 SINGAPORE
15.4.8 THAILAND
15.4.9 MALAYSIA
15.4.10 INDONESIA
15.4.11 PHILIPPINES
15.4.12 VIETNAM
15.4.13 REST OF ASIA-PACIFIC
15.5 SOUTH AMERICA
15.5.1 BRAZIL
15.5.2 ECUADOR
15.5.3 CHILE
15.5.4 COLOMBIA
15.5.5 VENEZUELA
15.5.6 ARGENTINA
15.5.7 PERU
15.5.8 CURAÇAO
15.5.9 PARAGUAY
15.5.10 URUGUAY
15.5.11 TRINIDAD AND TOBAGO
15.5.12 REST OF SOUTH AMERICA
15.6 MIDDLE EAST AND AFRICA
15.6.1 SOUTH AFRICA
15.6.2 SAUDI ARABIA
15.6.3 UAE
15.6.4 EGYPT
15.6.5 KUWAIT
15.6.6 ISRAEL
15.6.7 BOLIVIA
15.6.8 REST OF MIDDLE EAST AND AFRICA
15.7 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
16 GLOBAL DERMATITIS MARKET, SWOT AND DBMR ANALYSIS
17 GLOBAL DERMATITIS MARKET, COMPANY LANDSCAPE
17.1 COMPANY SHARE ANALYSIS: GLOBAL
17.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
17.3 COMPANY SHARE ANALYSIS: EUROPE
17.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
17.5 MERGERS & ACQUISITIONS
17.6 NEW PRODUCT DEVELOPMENT & APPROVALS
17.7 EXPANSIONS
17.8 REGULATORY CHANGES
17.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
18 GLOBAL DERMATITIS MARKET, COMPANY PROFILE
18.1 PFIZER, INC
18.1.1 COMPANY OVERVIEW
18.1.2 REVENUE ANALYSIS
18.1.3 GEOGRAPHIC PRESENCE
18.1.4 PRODUCT PORTFOLIO
18.1.5 RECENT DEVELOPMENTS
18.2 JOHNSON & JOHNSON (JANSSEN PHARMACEUTICALS)
18.2.1 COMPANY OVERVIEW
18.2.2 REVENUE ANALYSIS
18.2.3 GEOGRAPHIC PRESENCE
18.2.4 PRODUCT PORTFOLIO
18.2.5 RECENT DEVELOPMENTS
18.3 NOVARTIS AG
18.3.1 COMPANY OVERVIEW
18.3.2 REVENUE ANALYSIS
18.3.3 GEOGRAPHIC PRESENCE
18.3.4 PRODUCT PORTFOLIO
18.3.5 RECENT DEVELOPMENTS
18.4 AMGEN
18.4.1 COMPANY OVERVIEW
18.4.2 REVENUE ANALYSIS
18.4.3 GEOGRAPHIC PRESENCE
18.4.4 PRODUCT PORTFOLIO
18.4.5 RECENT DEVELOPMENTS
18.5 SANOFI
18.5.1 COMPANY OVERVIEW
18.5.2 REVENUE ANALYSIS
18.5.3 GEOGRAPHIC PRESENCE
18.5.4 PRODUCT PORTFOLIO
18.5.5 RECENT DEVELOPMENTS
18.6 BRISTOL MYERS SQUIBB
18.6.1 COMPANY OVERVIEW
18.6.2 REVENUE ANALYSIS
18.6.3 GEOGRAPHIC PRESENCE
18.6.4 PRODUCT PORTFOLIO
18.6.5 RECENT DEVELOPMENTS
18.7 BAYER AG
18.7.1 COMPANY OVERVIEW
18.7.2 REVENUE ANALYSIS
18.7.3 GEOGRAPHIC PRESENCE
18.7.4 PRODUCT PORTFOLIO
18.7.5 RECENT DEVELOPMENTS
18.8 ASTELLAS PHARMA INC
18.8.1 COMPANY OVERVIEW
18.8.2 REVENUE ANALYSIS
18.8.3 GEOGRAPHIC PRESENCE
18.8.4 PRODUCT PORTFOLIO
18.8.5 RECENT DEVELOPMENTS
18.9 REGENERON PHARMACEUTICALS, INC
18.9.1 COMPANY OVERVIEW
18.9.2 REVENUE ANALYSIS
18.9.3 GEOGRAPHIC PRESENCE
18.9.4 PRODUCT PORTFOLIO
18.9.5 RECENT DEVELOPMENTS
18.1 F-HOFFMANN LA ROCHE
18.10.1 COMPANY OVERVIEW
18.10.2 REVENUE ANALYSIS
18.10.3 GEOGRAPHIC PRESENCE
18.10.4 PRODUCT PORTFOLIO
18.10.5 RECENT DEVELOPMENTS
18.11 GLAXOSMITHKLINE PLC
18.11.1 COMPANY OVERVIEW
18.11.2 REVENUE ANALYSIS
18.11.3 GEOGRAPHIC PRESENCE
18.11.4 PRODUCT PORTFOLIO
18.11.5 RECENT DEVELOPMENTS
18.12 MERCK SHARP & DOHME CORP
18.12.1 COMPANY OVERVIEW
18.12.2 REVENUE ANALYSIS
18.12.3 GEOGRAPHIC PRESENCE
18.12.4 PRODUCT PORTFOLIO
18.12.5 RECENT DEVELOPMENTS
18.13 MYLAN NV
18.13.1 COMPANY OVERVIEW
18.13.2 REVENUE ANALYSIS
18.13.3 GEOGRAPHIC PRESENCE
18.13.4 PRODUCT PORTFOLIO
18.13.5 RECENT DEVELOPMENTS
18.14 TEVA PHARMACEUTICALS
18.14.1 COMPANY OVERVIEW
18.14.2 REVENUE ANALYSIS
18.14.3 GEOGRAPHIC PRESENCE
18.14.4 PRODUCT PORTFOLIO
18.14.5 RECENT DEVELOPMENTS
18.15 ASTRAZENCA
18.15.1 COMPANY OVERVIEW
18.15.2 REVENUE ANALYSIS
18.15.3 GEOGRAPHIC PRESENCE
18.15.4 PRODUCT PORTFOLIO
18.15.5 RECENT DEVELOPMENTS
18.16 AKORN
18.16.1 COMPANY OVERVIEW
18.16.2 REVENUE ANALYSIS
18.16.3 GEOGRAPHIC PRESENCE
18.16.4 PRODUCT PORTFOLIO
18.16.5 RECENT DEVELOPMENTS
18.17 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
18.17.1 COMPANY OVERVIEW
18.17.2 REVENUE ANALYSIS
18.17.3 GEOGRAPHIC PRESENCE
18.17.4 PRODUCT PORTFOLIO
18.17.5 RECENT DEVELOPMENTS
18.18 CIPLA PHARMACEUTICALS
18.18.1 COMPANY OVERVIEW
18.18.2 REVENUE ANALYSIS
18.18.3 GEOGRAPHIC PRESENCE
18.18.4 PRODUCT PORTFOLIO
18.18.5 RECENT DEVELOPMENTS
18.19 OTSUKA PHARMACEUTICALS
18.19.1 COMPANY OVERVIEW
18.19.2 REVENUE ANALYSIS
18.19.3 GEOGRAPHIC PRESENCE
18.19.4 PRODUCT PORTFOLIO
18.19.5 RECENT DEVELOPMENTS
18.2 GALDERMA
18.20.1 COMPANY OVERVIEW
18.20.2 REVENUE ANALYSIS
18.20.3 GEOGRAPHIC PRESENCE
18.20.4 PRODUCT PORTFOLIO
18.20.5 RECENT DEVELOPMENTS
18.21 ARENA PHARMACEUTICALS
18.21.1 COMPANY OVERVIEW
18.21.2 REVENUE ANALYSIS
18.21.3 GEOGRAPHIC PRESENCE
18.21.4 PRODUCT PORTFOLIO
18.21.5 RECENT DEVELOPMENTS
18.22 ASANA BIOSCIENCES
18.22.1 COMPANY OVERVIEW
18.22.2 REVENUE ANALYSIS
18.22.3 GEOGRAPHIC PRESENCE
18.22.4 PRODUCT PORTFOLIO
18.22.5 RECENT DEVELOPMENTS
18.23 ZYDUS HEALTHCARE
18.23.1 COMPANY OVERVIEW
18.23.2 REVENUE ANALYSIS
18.23.3 GEOGRAPHIC PRESENCE
18.23.4 PRODUCT PORTFOLIO
18.23.5 RECENT DEVELOPMENTS
18.24 ABBVIE
18.24.1 COMPANY OVERVIEW
18.24.2 REVENUE ANALYSIS
18.24.3 GEOGRAPHIC PRESENCE
18.24.4 PRODUCT PORTFOLIO
18.24.5 RECENT DEVELOPMENTS
18.25 GENZYME PHARMA
18.25.1 COMPANY OVERVIEW
18.25.2 REVENUE ANALYSIS
18.25.3 GEOGRAPHIC PRESENCE
18.25.4 PRODUCT PORTFOLIO
18.25.5 RECENT DEVELOPMENTS
18.26 GILEAD SCIENCES
18.26.1 COMPANY OVERVIEW
18.26.2 REVENUE ANALYSIS
18.26.3 GEOGRAPHIC PRESENCE
18.26.4 PRODUCT PORTFOLIO
18.26.5 RECENT DEVELOPMENTS
18.27 ELI LILLY
18.27.1 COMPANY OVERVIEW
18.27.2 REVENUE ANALYSIS
18.27.3 GEOGRAPHIC PRESENCE
18.27.4 PRODUCT PORTFOLIO
18.27.5 RECENT DEVELOPMENTS
18.28 TAKEDA PHARMACEUTICALS
18.28.1 COMPANY OVERVIEW
18.28.2 REVENUE ANALYSIS
18.28.3 GEOGRAPHIC PRESENCE
18.28.4 PRODUCT PORTFOLIO
18.28.5 RECENT DEVELOPMENTS
18.29 UCB PHARMA
18.29.1 COMPANY OVERVIEW
18.29.2 REVENUE ANALYSIS
18.29.3 GEOGRAPHIC PRESENCE
18.29.4 PRODUCT PORTFOLIO
18.29.5 RECENT DEVELOPMENTS
18.3 EISAI CO
18.30.1 COMPANY OVERVIEW
18.30.2 REVENUE ANALYSIS
18.30.3 GEOGRAPHIC PRESENCE
18.30.4 PRODUCT PORTFOLIO
18.30.5 RECENT DEVELOPMENTS
NOTE: THE COMPANIES PROFILED IS NOT EXHAUSTIVE LIST AND IS AS PER OUR PREVIOUS CLIENT REQUIREMENT. WE PROFILE MORE THAN 100 COMPANIES IN OUR STUDY AND HENCE THE LIST OF COMPANIES CAN BE MODIFIED OR REPLACED ON REQUEST
19 RELATED REPORTS
20 CONCLUSION
21 QUESTIONNAIRE
22 ABOUT DATA BRIDGE MARKET RESEARCH
